Purple Biotech Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
79.0%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$5.31next fiscal year
Monitoring Framework
Key Performance Indicators
Cash Runway Quarterly6.4Target: Runway into 2027
Preclinical Development of IM1240 (CAPTN-3 Platform) AnnuallyTarget: First-in-human clinical study initiation in 2027
Watch Items
- CEO TransitionTrigger: August 2026Action: Monitor the appointment of a new Chief Executive Officer to succeed Gil Efron, who is stepping down due to health considerations.
- CAPTN-3 Platform Preclinical MilestonesTrigger: Preclinical toxicology and efficacy data readoutsAction: Track additional efficacy evidence across potential indications and IND-enabling progress for IM1240.
- Strategic Partnering for CM24 and NT219Trigger: Execution of out-licensing or co-development agreementsAction: Evaluate potential partnerships or financing to resume active clinical development of CM24 and NT219 following the 2025 impairment.
Research as of 20 Jun 2026